Latest Tegaserod Stories
A panel of US Food and Drug Administration advisers voted Wednesday to allow GlaxoSmithKline's diabetes drug Avandia to remain on the market, but with new restrictions due to the risky cardiovascular side effects of the controversial pill.
CAMBRIDGE, Mass., Sept. 14 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that Thomas McCourt has joined the Company as chief commercial officer and senior vice president of marketing and sales. Mr.
The adult lower digestive tract can be stimulated to add neurons to the intestinal system, according to new mouse research in the August 5 issue of The Journal of Neuroscience.
Sucampo Pharma Europe, Ltd., a wholly-owned subsidiary of Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), today announced the results from three open-labeled, long-term (6 and 12 months) clinical trials of lubiprostone (AMITIZA(R)).
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced results of its phase 2b dose-ranging study of AMITIZA(R) (lubiprostone) in patients with Chronic Idiopathic Constipation (CIC), conducted in Japan.
By PETER GOTT Dear Dr. Gott: I took Zelnorm over a year ago, until my doctor said the Food and Drug Administration had taken it off the market and it was no longer available. Since I was suffering from chronic constipation, it was very helpful in regulating my system.
Callisto Pharmaceuticals, Inc. (Pink Sheets: CLSP; FWB: CA4), announced today that its Synergy Pharmaceuticals, Inc. closed a $3.0 million private placement.
Research and Markets (http://www.researchandmarkets.com/research/e40571/gastrointestinal_d) has announced the addition of the "Gastrointestinal Drug Discoveries: What the Future Holds" report to their offering.
Sucampo Pharmaceuticals and Takeda Pharmaceuticals North America have announced that Amitiza 8mcg capsules are now available by prescription in pharmacies across the US for the treatment of irritable bowel syndrome with constipation in women 18 years and older.
A new study shows that treating Irritable Bowel Syndrome (IBS) with constipation may have a significant impact on absenteeism from work, as well as improving presenteeism â€“ defined as coming to work but being less productive. Canadian researchers from The University of Alberta and Novartis Pharmaceuticals Canada presented findings of a study of tegaserod in patients with IBS characterized by constipation at the 70th Annual Scientific Meeting of the American College of Gastroenterology.